Romano, Carla C.Mendes-Giannini, Maria José Soares [UNESP]Duarte, Alberto J.S.Benard, Gil2014-05-272014-05-272002-07-25Cytokine, v. 18, n. 3, p. 149-157, 2002.1043-4666http://hdl.handle.net/11449/66938Treatment of patients with paracoccidioidomycosis is still a challenge. Patients present defective lymphoproliferation and IFN-γ responses to the main Paracoccidioides brasiliensis antigen (gp43), which correlates with disease severity. Here, we demonstrated that the patients show also a defective synthesis of interleukin (IL)-12. Therefore, we attempted to revert this immune disfunction by adding IL-12 and neutralizing anti-IL-10 antibody to gp-43-stimulated peripheral blood mononuclear cell cultures. Both treatments increased IFN-γ secretion to levels observed with healthy sensitized individuals, but affected proliferation only modestly. When combined, the treatments further increased IFN-γ synthesis and cell proliferation. The addition of suboptimal concentrations of IL-2 also further increased the IL-12-mediated secretion of IFN-γ. Interestingly, the immune modulation was mostly antigen-specific, since the responses to Candida albicans' antigen were not affected. These results suggest that appropriate immune intervention with cytokines and/or anti-cytokines may help in the treatment of PCM. © 2002 Elsevier Science Ltd. All rights reserved.149-157engInterleukin-10Interleukin-12Paracoccidioides brasiliensisParacoccidioidomycosisgamma interferonglycoproteinglycoprotein gp 43interleukin 10interleukin 12interleukin 2neutralizing antibodyunclassified drug43 kDa protein, Paracoccidioidesfungal proteinfungus antigenoligosaccharideadolescentadultagedcell proliferationcell stimulationclinical articlecontrolled studycytokine productioncytokine releasehumanimmune deficiencyimmune responseimmunomodulationlymphocyte proliferationmononuclear cellpriority journalschool childSouth American blastomycosisbiosynthesischilddrug antagonismdrug effectimmunological toleranceimmunologyin vitro studylymphocyte activationmiddle agedParacoccidioidesserodiagnosisAdolescentAdultAgedAntigens, FungalChildGlycoproteinsHumanImmune ToleranceIn VitroInterferon Type IILymphocyte ActivationMiddle AgeNeutralization TestsOligosaccharidesSupport, Non-U.S. Gov'tFungal ProteinsHumansMiddle AgedCandidaCandida albicansArtigo10.1006/cyto.2002.0884WOS:000177591000005Acesso restrito2-s2.0-00359972610000-0002-8059-0826